Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population Company to launch controlled study in second-line KRAS-mutant MSS mCRC with interim data expected by the end of 2026 Pelareorep now has Fast Track Designation for two gastrointestinal cancers, solidifying its potential as an immunotherapeutic platform therapy in gastrointestinal cancers SAN DIEGO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) ( ...

As a Private Company, Dayforce to Accelerate Growth, Customer Value, and AI Leadership in HCMMINNEAPOLIS and TORONTO and SAN FRANCISCO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Thoma Bravo, the world’s largest software-focused investment firm, today announced the completion of its acquisition of Dayforce, Inc. (“Dayforce” or the “Company”), a global human capital management (HCM) leader that makes work life better, for approximately US$12.3 billion. The agreement to acquire Dayforce was previously announced on Aug ...

Core Insights - The beginning of 2026 presents various challenges for advisors, including shifting rate expectations and valuation concerns in a top-heavy market [1] - Despite these challenges, ETFs have attracted significant investment, gathering an impressive $165 billion [1] Group 1 - Advisors are facing challenges related to changing interest rate expectations [1] - There are concerns regarding valuations in a market that is perceived as top-heavy [1] - The ETF market has shown resilience by accumulating $165 billion in investments [1]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists across key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered by the team includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Utilization - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company employs automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans to maintain best practices in content production and search engine optimization [5]

Core Insights - The article highlights the expertise of a seasoned equity analyst specializing in the U.S. restaurant industry, covering various segments from quick-service to fine dining [1] - The analyst employs advanced financial modeling and sector-specific KPIs to identify hidden value in public equities, particularly focusing on micro and small-cap companies often overlooked by mainstream analysts [1] Industry Focus - The research firm, Goulart's Restaurant Stocks, is dedicated to thematic research and valuation efforts within the restaurant sector, indicating a strong emphasis on understanding market dynamics and consumer trends [1] - The analyst also covers related sectors such as consumer discretionary, food & beverage, and casinos & gaming, showcasing a broad understanding of interconnected industries [1] Academic and Professional Background - The analyst possesses an MBA in Controllership and Accounting Forensics, along with a Bachelor's in Business Administration, providing a solid academic foundation for investment analysis [1] - Specialized training in valuation, financial modeling, and restaurant operations enhances the analyst's ability to conduct thorough research and provide valuable insights [1]

Core Insights - Silicon Motion Technology Corporation (SIMO) reported mixed fourth-quarter 2025 results, with revenues exceeding estimates while adjusted earnings fell short [1] Financial Performance - Net income on a GAAP basis improved to $47.7 million or $1.41 per American depositary share (ADS) from $21.6 million or 64 cents per ADS in the prior-year quarter, primarily due to higher net sales [3] - Non-GAAP net income was $42.7 million or $1.26 per ADS compared to $29.4 million or 87 cents per ADS in the year-ago quarter, missing the Zacks Consensus Estimate of $1.29 per ADS [3] - For 2025, GAAP net income was $122.6 million or $3.64 per ADS compared to $89.2 million or $2.65 per ADS in 2024 [4] - Non-GAAP net income for 2025 was $119.8 million or $3.55 per ADS compared to $114.5 million or $3.39 per ADS in 2024 [4] Revenue Growth - Quarterly revenues increased to $278.5 million from $191.2 million in the year-ago quarter, beating the Zacks Consensus Estimate of $261.2 million [5] - For 2025, revenues rose to $885.6 million from $803.6 million in 2024 [5] - Sales of SSD controllers increased by 35-40% year over year, while eMMC + UFS sales grew by 50-55%, and revenues in SSD solutions surged by 110-115% year over year [6] Profitability Metrics - Non-GAAP gross profit reached $137 million compared to $87.9 million in the year-ago quarter, with respective margins of 49.2% and 46% [7] - For 2025, non-GAAP gross profit increased to $427.9 million from $369.3 million in 2024, with margins of 48.3% and 46% [7] - Non-GAAP operating expenses rose to $83.2 million from $58.3 million in the prior year, but non-GAAP operating income increased to $53.8 million from $29.6 million, with margins of 19.3% and 15.5% respectively [8] Cash Flow and Liquidity - As of December 31, 2025, cash and cash equivalents were $201.8 million compared to $276.1 million a year ago [9] - The company generated $1.6 million in cash from operations during the reported quarter, down from $6.2 million in the prior-year quarter [10] - For 2025, cash generated from operating activities was $61.4 million compared to $77.1 million in 2024 [10] Future Guidance - For the first quarter of 2026, management estimates non-GAAP revenues in the range of $292-$306 million, with a gross margin expected to be between 46-47% [11]

Core Insights - Newmont Corporation (NEM) is enhancing shareholder value through significant dividends and share repurchases, distributing over $5.7 billion in the past two years [1][7] Financial Performance - Newmont generated a record free cash flow of $1.6 billion in Q3, with net cash from operating activities increasing by 40% year-over-year to $2.3 billion [2][7] - The company reduced its debt by approximately $2 billion in Q3, achieving a near-zero net debt position by the end of the quarter [3][7] Capital Allocation - Newmont has doubled its share repurchase authorization to $6 billion, executing $3.3 billion of this buyback as of October 23, 2025 [2] - The company is following a disciplined capital allocation policy, using its cash generation to return capital to shareholders, fund growth projects, and pay down debt [3] Market Position - Newmont's shares have increased by 79.2% over the past six months, outperforming the Zacks Mining – Gold industry, which rose by 64.8% [6] - The company is currently trading at a forward 12-month earnings multiple of 15.23, which is a 15% premium to the industry average of 13.24 [9] Earnings Outlook - The Zacks Consensus Estimate for NEM's earnings implies a year-over-year increase of 81.9% for 2025 and 21.1% for 2026, with EPS estimates trending higher over the past 60 days [10]

Core Viewpoint - VolitionRx Limited is sponsoring a symposium at the European Hidradenitis Suppurativa Foundation Conference to present findings on the Nu.Q NETs assay, which aids in the management of Hidradenitis Suppurativa (HS) through a precision medicine approach [1][2][3]. Company Overview - VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics and improving outcomes for patients through earlier detection and monitoring of diseases [11][12]. - The company is developing cost-effective blood tests for various diseases, including cancers and conditions associated with NETosis, aiming to enhance patient quality of life [12]. Industry Context - Hidradenitis Suppurativa (HS) is a chronic condition affecting approximately 1% of the global population, characterized by painful skin abscesses and scarring [3][9]. - The condition is difficult to manage, and the introduction of biological treatments has shown varied responses among patients, highlighting the need for a precision medicine approach [4][9]. Product and Market Potential - The Nu.Q NETs assay is CE-Marked for clinical use in 27 EU member states and is positioned as a simple, low-cost test to detect diseases associated with NETosis, with a total addressable market estimated at $3.8 billion [6][8]. - The assay aims to classify HS patients and guide treatment decisions, potentially improving patient management and outcomes [4][6].

8:30 a.m. Eastern Time Interested parties can listen to the call via live webcast. Please access 5-10 minutes before the call: PLANO, Texas--(BUSINESS WIRE)--Cinemark Holdings, Inc. ("Cinemark†) (NYSE: CNK), one of the largest and most influential theatrical exhibition companies in the world, today announced that it will report its fourth quarter and full year 2025 operating results pre-market and host a webcast and to discuss the results on: Wednesday, February 18, 2026 https://event.choruscall.com/media ...

Core Insights - GRI Bio, Inc. reported a cash position of $8.2 million as of December 31, 2025, and raised an additional $6.5 million in January 2026, strengthening its balance sheet to fund operations into Q1 2027 [1][4] - The company announced strong Phase 2a clinical data for GRI-0621 in idiopathic pulmonary fibrosis (IPF), reinforcing its clinical proof-of-concept and therapeutic differentiation [1][8] - GRI-0803, focused on autoimmune indications with high unmet need, is advancing through IND-enabling activities [1][8] Financial Summary - For the year ended December 31, 2025, GRI Bio reported a net loss of $12 million, with research and development expenses increasing to $6.8 million from $3.8 million in 2024, primarily due to the registration development program of GRI-0621 [5] - General and administrative expenses rose to $5.2 million in 2025 from $4.5 million in 2024, mainly due to increased personnel costs [6] Recent Highlights - The company raised approximately $14.5 million in gross proceeds in December 2025 and January 2026, ensuring a strong cash position to fund operations into Q1 2027 [8] - Positive Phase 2a topline data from the completed clinical study of GRI-0621 in IPF was announced, along with additional data demonstrating suppression of pro-fibrotic immune phenotypes [8] - New RNA-sequencing gene expression data was generated, showing a direct impact on the core biology of fibrosis and lung repair [8] - Plans to progress GRI-0803 into IND-enabling studies were advanced, expanding the company's pipeline in autoimmune diseases [8]